Introduction
Diseases of the cardiovascular system account for a significant proportion of deaths and serious illnesses in the UK at great cost, both financially and to individuals. Identification of modifiable risk factors for the development of cardiovascular disease offers potential for the development of strategies, both at individual and population levels, for the prevention of such diseases.
The origins of cardiovascular disease are complex, probably reflecting the interaction of multiple genetic and environmental factors in the development of disease. Because of the complex aetiology, largescale epidemiological studies are needed to identify such risk factors and to isolate them from confounding influences. Such studies have been instrumental in defining the risks associated with, amongst others, cigarette smoking, high blood pressure and elevated serum cholesterol levels.
Despite the identification and treatment of risk factors, the decline in cardiovascular mortality seen in recent decades is slowing. Further epidemiologCorrespondence: Dr JN Chapman, Department of Clinical Pharmacology, Division of NHLI, Imperial College School of Medicine, St. Mary's Hospital, London W2 1NY, UK E-mail: n.chapmanȰic.ac.uk ical studies are needed in order to identify further risk factors and to assess the impact of interaction among differing risk factors on cardiovascular outcomes. In addition, as far as possible, the conclusions of such studies need to be broadly generalisable. To this end, studies including female subjects and individuals from a wide variety of ethnic and social backgrounds, groups frequently excluded from existing epidemiological programmes, are essential.
Background and rationale
Cardiovascular disease accounts for almost half of the deaths in the UK. While previous and ongoing large-scale epidemiological studies have provided numerous insights into the effects of various risk factors on cardiovascular mortality, the relative importance of risk factors and how they interact remains largely unclear. In addition, the conclusions of such studies are often limited, either by the study design, population size, lack of recorded data or the extent to which the conclusions may be generalisable to the whole population.
The original Framingham Heart Study 1 prospectively followed a relatively small cohort of 5209, predominantly white, inhabitants of a small Massachusetts town. It provided important information on associations between cardiovascular disease and various risk factors, including increased total to high-density lipoprotein cholesterol levels, hypertension, cigarette smoking, excess weight, elevated blood sugar levels, lack of exercise and electrocardiographic abnormalities. Although these associations are clear, it is uncertain how far these findings can be extrapolated to the general population. Similarly, the British Regional Heart Study 2 has provided evidence of associations between cardiovascular mortality and blood pressure, smoking, alcohol and social class, among others. However, it was restricted to males only, as were the Whitehall study, 3 the Munster Heart Study PROCAM 4 and the Multiple Risk Factor Intervention Trial (MRFIT) 5, 6 screenee cohort. The Health Survey for England 7 collects annual cross-sectional data but, as yet, no prospective component is included within the design. Consisting of over 350 000 individuals, the cohort of MRFIT screenees 5, 6 was extensive. However the usefulness of this resource was restricted by baseline data which was limited to age, smoking status, serum cholesterol and blood pressure only. The Scottish Heart Health Study, 8 a prospective cohort study, used a comprehensive risk factor questionnaire as well as recording physical and biochemical parameters and an ECG but was limited to just over 10 000 participants.
Because of the complex aetiology of cardiovascular disease, it is necessary to study large groups of people in order to reduce the influence of confounding on individual risk factors. Recruitment for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) offers an opportunity to establish the largest UK cohort to date for the study of cardiovascular disease. It will have the additional advantages of including both male and female subjects as well as subjects from widely varying ethnic backgrounds, reflecting the diversity of ethnic groups in the UK.
For each subject recruited to ASCOT, it is estimated that three or more subjects will be screened. Thus, in the UK, an estimated 30 000 individuals will be screened during the recruitment phase. Stored information on these subjects, which would not otherwise be analysed in those screened who do not fulfil the entry requirements for ASCOT, will include historical data, blood pressure measurements, anthropomorphic measurements and biochemical and haematological parameters. Together with additional detailed information about known or potential cardiovascular risk factors, this may allow the identification of additional risk factors for cardiovascular disease and provide insight into the way in which individual environmental and genetic influences interact in the development of disease.
Objectives
The aim of the sub-study is to compile a comprehensive database of risk factors in a large group of individuals at risk of cardiovascular disease. A cohort of an estimated 30 000 individuals in the UK, screened during recruitment for ASCOT, will be prospectively identified and followed-up. Details of known and potential cardiovascular risk factors will be collected from a comprehensive self-administered questionnaire. This information, in addition to physical, anthropomorphic, biochemical and haematological variables will be stored in a computerised database. Participants will be registered with national databases for both mortality and morbidity.
The purpose of the cohort is to investigate the interaction of different cardiovascular risk factors and to assess their impact on cardiovascular disease outcomes. Data collected at baseline, supplemented by follow-up data from national morbidity and mortality databases will enable cross-sectional, retrospective and nested case-control studies and prospective cohort studies to be performed.
In addition to maintenance of a detailed database of clinical information and outcome data, all participants will have a 12-lead ECG recording available and blood stored. In combination, these will provide a valuable resource for testing future hypotheses on the subject of cardiovascular risk.
Study methods/design

Ethical approval and consent
The sub-study was approved by the Multi-Regional Ethics Committee and by local ethics committees at each ASCOT centre. All individuals attending screening visits at local centres ('screenees') are given information and invited to participate in the 
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Serum sample stored at −80°C samples sub-study. Individuals screened prior to commencement of the sub-study will be invited to take part retrospectively. Informed consent is sought to allow contact by telephone or follow-up questionnaire, to have access to medical records (GP, Hospital and via national registers) and for future analysis of stored blood samples.
Data collection, handling and storage
It is anticipated that approximately 30 000 individuals will be recruited. All individuals screened for ASCOT have historical, physical and laboratory variables recorded on a database. Routinely recorded variables are summarised in Table 1 . All individuals participating in the sub-study are asked to complete a self-administered questionnaire containing additional detailed questions on cardiovascular risk factors as summarised in Table 2 . Completed questionnaires will be collated at the coordinating centre. Data completeness will be checked and responses coded by research assistants. Data will be entered on a database compatible with the main ASCOT screening database. Source data validation will be performed on a sub-sample of the study population.
Follow-up
Screenees will be registered for cause of death via the Office of National Surveys (England and Wales), and with the Registrar General Deaths Registry (Scotland). All deaths will be notified to the coordinating centre and a copy of the death certificate made available. Verification of cause of death will be made using medical records and the cause of death coded according to the International Classification of Diseases, tenth revision. In Scotland the Scottish Record Linkage System monitors all hospital discharges and diagnoses. As a method of follow-up in epidemiological trials, it has been shown to be as effective as direct contact with patients. 12 Combining direct patient contact and computerised record linkage allows crosschecking of data while minimising the frequency of unreported events. In England and Wales, a similar system, the NHS-Wide Clearing System, has been established. All screenees will be registered for any hospitalisation for cardiovascular disease or cardiovascular procedure (eg, coronary artery bypass).
Analysis
Data collected at baseline will allow cross-sectional studies to evaluate inter-relationships between, for example, lifestyle variables (eg, smoking), ethnic group, social class, serum lipid levels and ECG abnormalities. Retrospective case-control studies may be used to compare prior exposures (eg, duration of hypertension) among those with various risk factors or conditions (eg, left ventricular hypertrophy) at baseline (cases) with those without such problems (controls).
Information derived from follow-up of subjects will allow major outcomes to be linked with baseline characteristics. By the use of nested casecontrol studies, data collected at screening will allow comparison of those who subsequently die or suffer a morbid event with those who do not, in relation to baseline variables. The presence of stored blood on all subjects means that baseline variables may also include haematological and biochemical variables measured retrospectively. This could be used to test hypotheses proposed in the future for cardiovascular risk factors.
Discussion
The ASCOT screenee database will represent a resource, in numbers and detail of information, unmatched by any existing cohort of UK adult hypertensives. Other screenee cohorts, although occasionally very large, have tended to record minimal information beyond that directly applicable to study entry. By analysis of baseline and follow-up data, this cohort will offer a unique opportunity to evaluate risk factors associated with the development of hypertension, target organ damage, mortality and non-fatal cardiovascular events. The detail of the recorded data will make it possible to look for those co-variables, beyond established risk factors, the presence of which may determine which individuals with risk factors proceed to a vascular event.
The introduction of computerised national databases of hospital admissions as well as mortality data will allow more complete and accurate followup of participants. This, together with the detail of recorded data, may further provide an opportunity to assess the accuracy and usefulness of current risk estimates (eg, the Framingham risk equation 13 and New Zealand cardiovascular risk charts 14 ) and potentially to create a new scoring system based on accumulated data.
Storage of blood on all subjects for future analysis means that the cohort may provide a useful resource for testing of future hypotheses about cardiovascular risk factors.
Inevitably the subjects in this cohort will not be randomly selected representatives of the general population and this may limit the generalisability of the findings. However, the results will be more relevant to high risk individuals than any other previous population-based findings which inevitably included small numbers of such patients. It should be recognised that subjects in the large landmark randomised controlled trials in cardiovascular medicine were volunteers who rarely represent the population from which they were drawn. Similarly, all major cohort studies are subject to criticisms of recruitment bias, whether participants are drawn from specific occupations (Whitehall 3 ), sexes (Physicians' Health Study 15 , Nurses Health Study 16 ), or non-randomly selected locations or populations (British Regional Heart Study, Rancho Bernado Concerns over the completeness and validity of the data from a self-administered questionnaire may be minimised by data monitoring and, where necessary, telephone contact with subjects by research workers. A sub-sample will undergo source data verification. The potential problem of regression dilution bias (eg, as a result of single measurements of blood pressure) may be addressed as subjects recruited into ASCOT will have repeated measurements prior to treatment, allowing the evaluation of the size of any such effect in screenees who do not enter ASCOT.
The cohort of ASCOT screenees is potentially the largest, most detailed, UK database of known and potential cardiovascular risk factors and the only one in high risk patients. The opportunity to register participants on national databases for mortality and morbidity, and the storage of blood for future, will offer a valuable opportunity to test future hypotheses about the origins and mechanisms of cardiovascular disease.
